CORRECTING and REPLACING MultiSafepay Supporting 20,000 SMEs to Scale Through Payment Integration and Digitisation with Antom Technology Engine
17.4.2025 15:36:00 CEST | Business Wire | Press release
MultiSafepay, the Amsterdam-based digital payment provider, now serves 20,000+ SME merchants across Europe, with merchant numbers growing 11% since its strategic integration with Antom, empowering thousands of businesses to thrive. Transaction volumes have surged, growing by 44% YoY, driven organically by rapid deployment of POS solutions and collaboration with Antom. Ant International has opened a new office in Amsterdam’s City Centre for MultiSafepay which enables more efficient collaboration with Ant International’s other business pillars.
Seventh paragraph, first sentence should read: Today, 8% of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments. (instead of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments.).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417858076/en/
Ant International’s new office in Amsterdam City Centre will house MultiSafepay’s operations and enable further collaboration between its business pillars.
The updated release reads:
MULTISAFEPAY SUPPORTING 20,000 SMES TO SCALE THROUGH PAYMENT INTEGRATION AND DIGITISATION WITH ANTOM TECHNOLOGY ENGINE
- MultiSafepay, the Amsterdam-based digital payment provider, now serves 20,000+ SME merchants across Europe, with merchant numbers growing 11% since its strategic integration with Antom, empowering thousands of businesses to thrive.
- Transaction volumes have surged, growing by 44% YoY, driven organically by rapid deployment of POS solutions and collaboration with Antom.
- Ant International has opened a new office in Amsterdam’s City Centre for MultiSafepay which enables more efficient collaboration with Ant International’s other business pillars.
MultiSafepay (MSP), an Amsterdam-based payment service provider, which became part of Ant International’s Antom, reported strong growth since its strategic integration with Antom, supporting thousands more SMEs in Europe to scale through innovative solutions.
Since announcing its acquisition in July 2024, MSP has expanded its merchant base across Europe to 20,000+, an 11% increase. Transaction volumes surged by 44% year-on-year, reflecting customers' robust business growth as well as the addition of new top industry performers. Merchants are increasingly moving to unified payment services, in-person payments are now already at 8% of total volume processed across retail and food & beverage verticals - demonstrating the value of increased efficiency in operations and the benefits of enhancing customer touchpoints.
This acceleration displays the potential of Antom’s post-acquisition strategy to combine local expertise with a global technology suite, benefiting the merchants MSP serves with innovative digital technologies.
MSP provides merchants with unified payment capabilities, supporting more than 40 local and international payment methods, including cards, e-wallets, Buy Now Pay Later, internet banking, across in-person and online channels.
Since becoming wholly-owned subsidiary of Ant International, MSP has been integrating with Antom to help businesses improve operations, and scale with confidence, using the powerful solutions relied on by industry leaders globally. MSP will also look to work with other businesses of Ant International such as WorldFirst to offer inclusive financial services to its SME merchant base.
In under a year, the integration has propelled innovation for merchant expansion, improvements in payment success rates, and infrastructure upgrades, demonstrating the power of combining MSP’s 25-years of expertise with Antom’s global experience.
Today, 8% of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments. Supporting a range of technology gives merchants a flexible, cost-effective way to handle payments and demonstrates MSP’s dedication to helping small businesses thrive by offering a solution that fits their unique needs.
Olaf Geurs, CEO of MultiSafepay, commented: “We expect to exceed our 2025 growth projections given current strong numbers and deepened partnership with Ant International. The data shows how SME partners are embracing our joint innovative solutions with Antom to accelerate their digital operations. MultiSafepay's momentum underscores the value of our collaboration in empowering businesses to succeed in today's fast-evolving world.”
“Accelerating the adoption of new technologies like AI in merchant payment services enable us to raise efficiency while maximizing our expertise in the SME sector,” said Gary Liu, General Manager of Antom, Ant International. “By building on MultiSafepay’s platform and Antom’s global expertise, we’re making simple, flexible payments accessible to every business - no matter their size or ambition.”
The company has recently moved to Ant International’s new office in Amsterdam’s vibrant City Centre, enabling collaborations with other Ant International business pillars to directly benefit SMEs.
About Antom
Ant International's Antom is the leading payment and digitisation services provider for merchants around the world. It offers unified merchant payment solutions to serve businesses of all sizes. Antom supports merchants in over 50 countries and regions, enabling them to connect with consumers in more than 200 markets, with the flexibility to accept payments in more than 100 currencies. Beyond payments, it provides digital marketing solutions and merchant digitisation services to help merchant streamline operations and enhance customer engagement.
To learn more, please visit https://www.antom.com/.
About MultiSafepay
MultiSafepay is a leading Amsterdam-based payment service provider, combining decades of expertise with powerful in-house technology to help every business grow faster and compete with confidence, no matter their size or ambition.
By leveling the playing field in payments, we offer European businesses a simple, flexible solution for online, in-person, and unified payments, all through a single platform and integration. With a personal approach to payments, we optimize success rates, reduce complexity, and help your business do more, and earn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250417858076/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom